Ann: Quarterly Update, page-185

So just to reiterate - we need to continue Zero Churn. If we have gone down the high volume/low price route, then the product has to perform and prove its value to the customer.
If in 12months time they all re- sign, now at their own cost - then this company is a mini cochlear, purely on the aged care/dementia market alone. $2/share
So I’m hoping the government then insist it is used as the “new standard in pain assessment” which also gives them a option to keep tabs on the care being given.
all in my opinion
interesting times